
Sign up to save your podcasts
Or


In this episode, we discuss the concept of professional advocacy, with a particular focus on how to advocate for the profession of pharmacy and what tools and organizations are available to assist in being an advocate.
In this episode, we discuss with Dr. Megan Hartranft the five oncology drugs that every pharmacist should know about, which is a great review for P4 students who are currently preparing for the NAPLEX. We cover cyclophosphamide, cisplatin, methotrexate, doxorubicin, and vincristine.
In this episode, we discuss the newest definition of sepsis and septic shock according to the Sepsis-3 criteria and the 2016 Surviving Sepsis guidelines. We also review the scoring systems of "qSOFA" and "SOFA" and use a patient case to help demonstrate the new definitions.
In this episode, we discuss the overuse of proton pump inhibitor (PPI) therapy and several concerns regarding chronic use of this medication class, including hypomagnesemia, fracture risk, low seurm B12 levels, anemias, and increased risk of certain infections.
In this episode, we discuss the new FDA categorizations of biosimilars, the legal implications of biologic/biosimilar prescriptions, and the new "follow-on" approval pathway of Basaglar, a new insulin glargine U-100 product.
In this episode, we discuss the SPRINT trial (intensive vs. standard blood pressure control) using a case vignette of Mr. Wilson, a 55 year old patient presenting to a clinic with a blood pressure of 139/89 mmHg.
In this episode, we discuss precepting tips and clinical pearls with Dr. Brad Cannon.
In this episode, we discuss more of the most important drug interactions, including grapefruit juice with statins and calcium channel blockers, QT prolonging medications, levothyroxine with cations and PPIs, and PDE-5 inhibitors with nitrates.
In this episode, we discuss some of the most important drug interactions, including serotonin syndrome, St. John's wort, statins and CYP inhibitors, and antihypertensive medications with NSAIDs.
In this episode, we discuss two new naloxone devices (intramuscular Evzio and intranasal Narcan) and review new state laws that are expanding the role of pharmacists in dispensing these opioid reversal products.
From the publisher's feed

43,315 Listeners

693 Listeners

498 Listeners

264 Listeners

3,341 Listeners

56,392 Listeners

1,157 Listeners

16,948 Listeners

402 Listeners

733 Listeners

299 Listeners

194 Listeners

516 Listeners

110 Listeners

156 Listeners